VWK147
VWK147 is a second-generation HSP90 C-terminal domain (CTD) inhibitor. VWK147 targets the CTD dimerization interface, prevents HSP90 CTD dimerization, disrupts co-chaperone PPID binding to HSP90 CTD, and inhibits HSP90 chaperone function dependent on dimerization. VWK147 reduces protein levels of HSP90 client proteins ULK1, RIPK1, and CDK4 without inducing a heat shock response. VWK147 induces cell death, including apoptosis, in Cisplatin (HY-17394)-sensitive and -resistant urothelial carcinoma cells. VWK147 induces LC3-II accumulation, inhibits autophagosome-lysosome fusion to block canonical autophagy, and induces non-canonical LC3 lipidation independent of ULK1 and PIK3C3 complexes. VWK147 can be used for the research of urothelial carcinoma.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Formule: C32H38N10O7
- Masse moléculaire:674.71
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
|
HSP90 |
ULK1 |
CDK4 |
RIPK1 |
VWK147 inhibits the interaction between HSP90β CTD and PPID in a TR-FRET assay[1].
VWK147 (10 μM; 3 h) does not bind to the HSP90 NTD in a fluorescence polarization assay[1].
VWK147 (25-100 μM; 1 h) inhibits HSP90 chaperone function in a cell-free luciferase refolding assay[1].
VWK147 (2-50 μM; 1 h) reduces HSP90α CTD dimers in a BS3 crosslinker assay[1].
VWK147 (1-10 μM; 6 h) destabilizes HSP90 client proteins ULK1, RIPK1, and CDK4 in Cisplatin-sensitive T24 and Cisplatin-resistant T24-CR urothelial carcinoma cells[1].
VWK147 (0.1-100 μM; 72 h) reduces cell viability in Cisplatin-sensitive (253J, T24) and -resistant (253J-CR, T24-CR) urothelial carcinoma cells with IC50 values of ~3-5 μM after 72 h[1].
VWK147 (10 μM; 0-24 h) induces cell death with both apoptotic and necrotic properties in T24 and T24-CR urothelial carcinoma cells over 24 h[1].
VWK147 (5 μM; 24 h) induced cell death in 253J, 253J-CR, T24, and T24-CR urothelial carcinoma cells is partially caspase-dependent[1].
VWK147 (1-10 μM; 6 h) induces concentration-dependent PARP1 cleavage in T24 and T24-CR urothelial carcinoma cells[1].
VWK147 (5 μM; 1-24 h) induces time-dependent PARP1 cleavage in T24 and T24-CR urothelial carcinoma cells over 24 h[1].
VWK147 (5 μM; 0-24 h) induces caspase-3 activation in Cisplatin-sensitive (253J, T24) and -resistant (253J-CR, T24-CR) urothelial carcinoma cells over 24 h[1].
VWK147 (5 μM; 6 h) inhibits autophagic flux in T24 and T24-CR urothelial carcinoma cells, as shown by LC3-II accumulation[1].
VWK147 (5 μM; 4 h) inhibits autophagosome-lysosome fusion in T24 and T24-CR urothelial carcinoma cells stably expressing mRFP-EGFP-rLC3[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Cisplatin-sensitive (T24) and -resistant (T24-CR) urothelial carcinoma cells
-
Concentration:1 μM, 3 μM, 5 μM, 10 μM
-
Incubation Time:6 h
-
Result:Reduced levels of HSP90 client proteins ULK1, RIPK1, and CDK4 in both T24 and T24-CR cells.\nDid not increase levels of HSP27, HSP40, or HSP70.
-
Cell Line:Cisplatin-sensitive (253J, T24) and -resistant (253J-CR, T24-CR) urothelial carcinoma cells
-
Concentration:0.1-100 μM
-
Incubation Time:72 h
-
Result:Reduced cell viability in all four cell lines with IC50 values of ~3-5 μM for 253J, ~3-5 μM for 253J-CR, ~3-5 μM for T24, and ~3-5 μM for T24-CR.
-
Cell Line:253J, 253J-CR, T24, and T24-CR urothelial carcinoma cells
-
Concentration:5 μM (with 20 μM Q-VD-OPh (HY-12305) as co-treatment)
-
Incubation Time:24 h
-
Result:Had its mediated cell viability reduction partially reduced by Q-VD-OPh but not abolished, indicating partial pro-apoptotic effects.
-
Cell Line:T24 and T24-CR urothelial carcinoma cells
-
Concentration:1-10 μM
-
Incubation Time:6 h
-
Result:Increased cleaved PARP1 levels in a concentration-dependent manner in both cell lines.
-
Cell Line:T24 and T24-CR urothelial carcinoma cells
-
Concentration:5 μM
-
Incubation Time:1-24 h
-
Result:Induced time-dependent PARP1 cleavage, with increased cleavage over 24 h.
-
Cell Line:T24 and T24-CR urothelial carcinoma cells
-
Concentration:5 μM (with 20 nM bafilomycin A1 as co-treatment)
-
Incubation Time:6 h
-
Result:Increased LC3-II levels with mono-treatment, but combination with Bafilomycin A1 did not further increase LC3-II levels, indicating inhibited autophagic flux; p62 levels were unaffected.
-
Cell Line:T24 and T24-CR cells stably expressing mRFP-EGFP-rLC3
-
Concentration:5 μM
-
Incubation Time:4 h
-
Result:Resulted in almost complete co-localization of GFP and RFP signals (yellow structures), indicating inhibited autophagosome-lysosome fusion (no red-only puncta).
-
Cell Line:T24 and T24-CR urothelial carcinoma cells
-
Concentration:5 μM (with 5 μM SAR405 as co-treatment)
-
Incubation Time:4 h
-
Result:Induced LC3-positive aggregates that were unaffected by SAR405, indicating PIK3C3-independent (non-canonical) LC3 lipidation.
Chemical Information
-
Masse moléculaire 674.71
-
Formule C32H38N10O7
-
SMILES
CCC(N1C(C(NC(C2=NC=C(C(N2CC3=CC=C(C=C3)OC)=O)N)=O)=CN=C1C(NC4=CN=C(N(C4=O)CC(C)C)C(NC)=O)=O)=O)C
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
VWK147 Related Classifications
HY-181062 Related Classifications
Powered by Bioz